Inclusion Criteria:

• * Referred for a clinically indicated CT-MPI for CAD assessment
• * Must provide written informed consent prior to any study-related procedures being performed
• * Must be willing to comply with all clinical study procedures

Exclusion Criteria:

• * Pregnant or nursing females. The possibility of pregnancy will be excluded by testing (serum or urine ßHCG) within 24 hours before study agent administration, or if the woman has previous surgical sterilization, or if the woman is post menopausal, with minimum one (1) year history without menses.
• * Currently taking or has taken within 48 hours the following excluded medications:
• * ActoPlus Met (Pioglitazone + metformin)
• * Avandamet (Rosiglitazone + metformin)
• * Fortamet (metformin)
• * Glucovance (Glyburide +metformin)
• * Glucophage (metformin)
• * Glucophage extended-release (XR) (metformin)
• * Glumetza (metformin)
• * Janumet (Sitagliptin + metformin)
• * Metformin
• * Metaglip (Glipizide + metformin)
• * Riomet (metformin)
• * Implanted rhythm devices (pacemaker, defibrillator)
• * Acute psychiatric disorder
• * Unwilling to comply with the requirements of the protocol
• * Previously entered this study
• * Known hypersensitivity to iodinated contrast material, beta-blockers, or pharmaceutical stressors used in this study
• * Suffers from claustrophobia
• * Impaired renal function (GFR \< 45 ml/min)
• * Acute hypotension (\<100 mm Hg systolic)
• * 2nd or 3rd degree atrioventricular (AV) block